Luxembourg Venture Days to Unite Investors, Startups and Innovators on 16 and 17 October 2024

7.10.2024 17:57:00 EEST | Business Wire | Press release

The second edition of the Luxembourg Venture Days will gather investors, startups, and innovators in a joint summit on 16 and 17 October 2024 at Luxexpo The Box. The annual event is organised by Luxembourg’s innovation agency Luxinnovation and the Luxembourg Private Equity and VC Association (LPEA) under the umbrella of Startup Luxembourg, the country’s network to promote its startup ecosystem. This event offers a unique opportunity for investors and startups to convene, exchange, liaise and explore new strategic and investment horizons.

Luxembourg’s stands as a pivotal financial hub offering various services that attract leading investors and markets around the world. It also built a robust, stable, diversified and thriving economy and is home to around 550 startups and 15 incubators, accelerators, and innovation hubs.

The country boasts a dynamic network of business angels, with a growing number of locally managed venture capital funds.

Luxembourg’s position within a 'Greater Region' (comprising bordering territories of France Germany and Belgium) with 12 million inhabitants, its agility and accessibility, coupled with its business-friendly climate, a pragmatic approach, and an easy access to key decision-makers, makes it a hub, bridge, and springboard for investors and startups in strategic and flourishing domains such as, fintech, space, climate, health, logistics, and mobility. It attracts and invites them to participate in shaping an ecosystem with international reach that inspires innovation and fosters sustainable growth.

The growing number of European unicorns (i.e. startups valued at one billion US dollars or more) shows the progress that the European startup ecosystem has made over the past years. Matchmaking platforms and networks that connect startups and investors are key to maintain and further accelerate this momentum. Luxembourg, as an international business hub and gateway at the heart of Europe, is well positioned to stimulate the interaction between investors and entrepreneurs.

“Luxembourg is a hub, bridge, and springboard for investors and startups to explore opportunities and forge partnerships in strategic domains,” says Sasha Baillie, CEO of Luxinnovation. “The Luxembourg Venture Days will bring together several renowned and high-level events under one roof. For startups, it will be an excellent opportunity to pitch in front of a variety of investors. For investors, it will be a place to team up and find new partners and investments. We are proud to join forces with these main actors to develop our new win-win event formula and foster Luxembourg’s role as a vibrant ecosystem, home and hub for startups and investors.”

“Luxembourg is an important hub for private equity and venture capital investors as it provides an agile and accessible platform for established actors and newcomers who want to keep abreast of developments, explore new avenues, grow their investments, and create added value,” adds Stephane Pesch, CEO of LPEA.”

Registration and agenda: Luxembourg Venture Days.

The highlights of Luxembourg Venture Days 2024:

Fit 4 Start pitching sessions (16 + 17 October)
Pitch of 60 pre-selected startups and selection 20 for the next Fit 4 Start edition
LPEA annual Insights Conference (17 October)
Full-day programme with panels and an exclusive pitching event
Keynote and masterclasses for investors and startups by US VC Jillian Manus (16 October)
Other pitch, demo, networking, and match-making sessions (16 + 17 October)
- Tomorrow Street matchmaking breakfast with scale-ups (16 October)
- Gener8tor Demo Day (17 October)
- Luxembourg Business Angel Network (LBAN) reverse pitch (17 October)
- Luxembourg Open Innovation Club (LOIC)/ Luxinnovation Reverse Pitch (16 October)
- 8 pioneering startups to discover (17 October) – Lunch with eight Influential startups embodying our ecosystem’s potential
Presentation of the first-ever Dealroom report on EU-backed startups (16 October)
Presentation of the report “Titans of Tech” 2024 by European VC GP Bullhound (16 October)
- Exclusive VC networking dinner (16 October)
Insightful panel discussions (16 + 17 October)
- The value and benefits of investing in women-led startups (17 October)
- Navigating term sheet negotiations with investors (16 October)
General closing ceremony (17 October) –- -Joint-programme for the large audience with:
- Keynotes by several leading profiles, including Marjut Falkstedt, CEO of the European Investment Fund
- Roundtable discussions
- Announcement of the 20 startups selected for Fit 4 Start #15; followed by a networking cocktail.

About Luxinnovation: as the national innovation agency, we empower companies to innovate today to be ready for tomorrow. We contribute to the development of the economy as a whole by identifying innovation opportunities and fostering collaborative innovation projects that stimulate the development of a sustainable, competitive and digital economy. Set up as an Economic Interest Group, Luxinnovation is supported by the Ministry of the Economy, the Ministry for Research and Higher Education, the Ministry of Foreign and European Affairs, the Luxembourg Chamber of Commerce, the Luxembourg Chamber of Skilled Crafts and FEDIL – The Voice of Luxembourg’s Industry. www.luxinnovation.lu

The Luxembourg Private Equity and Venture Capital Association (LPEA) is the most trusted and relevant representative body of private equity and venture capital practitioners with a presence in Luxembourg. Created in 2010 by a leading group of private equity and venture capital players in Luxembourg, with more than 530 members today, LPEA plays a leading role locally actively promoting PE and VC in Luxembourg. LPEA provides a dynamic and interactive platform which helps investors and advisors to navigate through latest trends in the industry. www.lpea.lu

Startup Luxembourg is the unique brand of Luxembourg's startup ecosystem, aiming at showcasing its players and innovators inside and outside the country. This is a public initiative funded by the Ministry of the Economy and managed by Luxinnovation.
www.startupluxembourg.com

View source version on businesswire.com: https://www.businesswire.com/news/home/20241004816914/en/

Contacts

About Business Wire

For more than 50 years, Business Wire has been the global leader in press release distribution and regulatory disclosure.

www.businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 20:52:00 EEST | Press release

International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he has served as pro bono counsel to five Nobel Peace Prize laureates. The New York Times has referred to him as "The Extractor" for his work freeing political prisoners worldwide. Genser's decision to support Yim Leak's team comes as the businessman faces an asset freeze exceeding 20 billion baht (more than U

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 18:38:00 EEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli ® (Relacorilant)18.9.2026 15:00:00 EEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu ® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 15:00:00 EEST | Press release

Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at the 2025 European Society for Medical Oncology (#ESMO25) Congress and subsequently published in The New England Journal of Medicine. The recommendation will now be reviewed by the European Commission, which has the authority to grant marketing authorizations for medicines in the EU. In DES

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca ® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 13:58:00 EEST | Press release

Alfasigma S.p.A, a global pharmaceutical company with a focus on innovation in rare disease and specialty care in areas where there is significant unmet patient need, today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) has issued a positive opinion for Jyseleca® (filgotinib), an oral, once-daily JAK1 preferential inhibitor, for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy. Following this positive opinion, the application is now referred to the European Commission (EC) for final action. The EC’s decision is expected in the next weeks. “At present, half of people living with axSpA fail to adequately respond to treatment, leaving them with years of preventable struggle with persistent pain and other impactful symptoms,” said Daniele D'Ambrosio, Chief Development Officer, Alfasigma. “This

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom